Compare Johnson & Johnson (JNJ) vs Global X NASDAQ 100 Covered Call ETF (QYLD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs Global X NASDAQ 100 Covered Call ETF — how do they compare? Johnson & Johnson trades at $261.07 (market cap $618.09B), while Global X NASDAQ 100 Covered Call ETF trades at $18.69 (market cap $8.49B). The key difference: Johnson & Johnson is far larger — about 72.8× Global X NASDAQ 100 Covered Call ETF's market cap, and Johnson & Johnson pays a 2.09% dividend while Global X NASDAQ 100 Covered Call ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Johnson & Johnson for 129 Days and Global X NASDAQ 100 Covered Call ETF for 51 Days on average.
| JNJ | QYLD | |
|---|---|---|
Market Cap | $618.09B | $8.49B |
Volume | 6,050,983 | 2,913,938 |
Sector | Health | Income / Options Overlay |
52-Week High | $278.43 | $18.68 |
52-Week Low | $186.00 | $16.70 |
Typical Hold Time | 129 Days | 51 Days |
Enterprise Value | $646.37B | — |
Dividend Yield | 2.09% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $261.44, up 1.16% with a bearish technical signal despite recent earnings beats. The company maintains strong fundamentals with $94.19B revenue, 21.48% net margin, and consistent dividend payments. Recent news highlights growth in the Innovative Medicine segment and positive analyst coverage with a $286.53 consensus target.
JNJ offers stable growth potential with diversified healthcare operations and robust profitability. Key risks include patent expirations, competitive pressures, and debt levels. Analyst consensus leans bullish with 52.5% buy ratings, though technical indicators suggest near-term caution. The stock presents a balanced opportunity for long-term investors seeking healthcare exposure.
QYLD trades at $18.685 with minimal daily movement (+0.03%), showing technical bullish signals from moving averages but bearish oscillator readings including overbought RSI levels. The ETF maintains consistent monthly dividend distributions of $0.18 per share, though recent news highlights concerns about declining option premiums and long-term capital erosion despite the attractive yield.
The outlook remains cautious as covered call strategies limit upside participation during market rallies. While providing reliable income, QYLD faces structural headwinds including capped growth potential and potential tax reclassification of distributions. Investors should weigh the trade-off between high current yield and long-term total return potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About Global X NASDAQ 100 Covered Call ETF
QYLD is an ETF that follows a covered call strategy on the NASDAQ 100 Index. The fund holds a long position in the stocks of the NASDAQ 100 and simultaneously writes (sells) call options on the index. The primary goal is to generate monthly income from the option premiums. This strategy can reduce portfolio volatility and provide income, but it limits potential capital appreciation from a significant rise in the NASDAQ 100 Index.
Read more on QYLD →
